<DOC>
	<DOCNO>NCT01847573</DOCNO>
	<brief_summary>The main purpose study test safety tolerability different , increase dos experimental medication call HT-100 boy young men Duchenne muscular dystrophy ( DMD ) . The study medication , HT-100 , medicine may help promote healthy muscle regeneration , diminish inflammation result damage muscle , decrease scar tissue form muscle child DMD . In study , pharmacokinetic sampling , measurement amount HT-100 bloodstream also take .</brief_summary>
	<brief_title>Safety , Tolerability , Pharmacokinetics Single Multiple Doses HT-100 Duchenne Muscular Dystrophy</brief_title>
	<detailed_description />
	<mesh_term>Muscular Dystrophies</mesh_term>
	<mesh_term>Muscular Dystrophy , Duchenne</mesh_term>
	<mesh_term>Halofuginone</mesh_term>
	<criteria>Main Ambulatory nonambulatory Diagnosis DMD confirmation minimal dystrophin Corticosteroid naive therapy least 12 month ( stable dose regimen ) Main Recent , substantial change use cardiac medication medication affect muscle function Inability undergo magnetic resonance imaging ( MRI ) Significantly compromise cardiorespiratory function Prior treatment another investigational product past 6 month</criteria>
	<gender>Male</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>20 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>halofuginone hydrobromide</keyword>
	<keyword>anti-fibrotic</keyword>
	<keyword>anti-inflammatory</keyword>
	<keyword>muscle regeneration</keyword>
	<keyword>protein synthesis inhibitor</keyword>
</DOC>